ABC Family Arquivos Brasileiros de Cardiologia International Journal of Cardiovascular Sciences ABC Heart Failure & Cardiomyopathy ABC Imagem Cardiovascular
Português English
ABC Family
Português English
  • About
    • About ABC Family
    • Internal Regulation
    • Editorial Board
    • Brazilian Society of Cardiology (SBC)
  • Issues
  • SBC Guidelines
  • Content
    • Videos
    • Podcasts
    • News
  • About
    • About ABC Family
    • Internal Regulation
    • Editorial Board
    • Brazilian Society of Cardiology (SBC)
  • Issues
  • SBC Guidelines
  • Content
    • Videos
    • Podcasts
    • News

ABC Family

  • ABC Family
  • Arquivos Brasileiros de Cardiologia
  • International Journal of Cardiovascular Sciences
  • ABC Heart Failure & Cardiomyopathy
  • ABC Imagem Cardiovascular
Search in

No content found.

Journals
Ordering
Article types
Others

  1. Home
  2. Keyword: Phosphodiesterase Inhibitors
Figure 1
ABC
Case Report

Sildenafil for Noncompaction Cardiomyopathy Treatment in a Child: Case Report

Ana Carolina Costa Redondo et al. Gabriela Fuenmayor Karen Saori Shiraishi Simone Rolim F Fontes … Patrícia Figueiredo Elias Rogerio Souza Ieda Biscegli Jatene

Introduction

Congestive heart failure (CHF) occurs when the heart can no longer maintain the baseline metabolic demand triggered by physiological venous pressure. In the pediatric population, it corresponds to a complex entity with multiple etiologies, depending on the age group assessed, being mainly associated with congenital structural malformations, cardiomyopathies, or secondary to arrhythmogenic, infectious, ischemic, toxic or infiltrative events.

The incidence of CHF in children also varies according to the underlying condition, ranging from 15% to 25% in patients with congenital heart defects. In structurally normal hearts, cardiomyopathy is the major factor associated with CHF, with a 40% incidence of CHF reported in those patients.

[…]

  • Cardiomyopathy, Dilated/complications
  • Heart Failure
  • Phosphodiesterase Inhibitors
Read Full Article
Creative Commons Attribution (CC BY) Creative Commons license
01/03/2014 DOI: 10.5935/abc.20140024 Views 2
Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption
ABC
Artigo Original

Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption

Adauto Carvalho Silva et al. Odaly Toffoletto Luiz Antonio Galvão Lucio Paula Ferreira dos Santos … Jorge Barros Afiune João Massud Filho Sergio Tufik

BACKGROUND: Millions of men around the world suffer from erectile dysfunction, for which phosphodiesterase 5 inhibitors (PDE-5 inhibitors) are currently the first treatment option. Sexual activity and alcohol consumption are closely related, and the simultaneous use of alcohol and PDE-5 inhibitors can happen. Lodenafil carbonate is a new PDE-5 inhibitor, developed by a Brazilian pharmaceutical company. OBJECTIVE: This work aimed at evaluating the cardiovascular safety of lodenafil carbonate, with and without simultaneous alcohol consumption. METHODS: Fifteen male volunteers received 160 mg lodenafil carbonate (LC), in three different moments. Participants were assigned to three groups, treated with LC in fasting condition, with alcohol or receiving only placebo. The volunteers were continuously monitored during 24 hours for physical impairment, blood pressure, heart rate, QT interval and lodenafil’s pharmacokinetic parameters. RESULTS: Lodenafil carbonate alone or with alcohol did not induce clinically relevant modifications in arterial blood pressure or heart rate. A statistically significant decrease in blood pressure was seen four hours after LC and alcohol intake, and an increase in heart rate six hours after intake of lodenafil carbonate alone. The QTc interval was not significantly modified. Lodenafil carbonate bioavailability was increased in 74% when drug intake was associated with alcohol. CONCLUSION: These results show that the use of lodenafil carbonate did not have clinically relevant effects on blood pressure or heart rate, and was not associated with QT interval prolongation. The association of lodenafil carbonate and alcohol affected its pharmacokinetic properties, increasing the bioavailability of the drug.

  • Alcohol Drinking
  • attributable risk
  • Cardiovascular System
  • erectile dysfunction
  • Phosphodiesterase Inhibitors
Read Full Article
Creative Commons Attribution (CC BY) Creative Commons license
05/05/2010 DOI: 10.1590/S0066-782X2010000200004 Views 2

How to cite this article

EndNote RIS

Electronic Document Format (Vancouver)

Redondo ACC, Fuenmayor G, Shiraishi KS, Fontes SRF, Elias PF, Souza R, Jatene IB, et al. Sildenafil for Noncompaction Cardiomyopathy Treatment in a Child: Case Report. Arquivos Brasileiros de Cardiologia 2014;102(3):27.

Electronic Document Format (ABNT)

Redondo, Ana Carolina Costa; Fuenmayor, Gabriela; Shiraishi, Karen Saori; Fontes, Simone Rolim F; Elias, Patrícia Figueiredo; Souza, Rogerio; Jatene, Ieda Biscegli. Sildenafil for Noncompaction Cardiomyopathy Treatment in a Child: Case Report. Arquivos Brasileiros de Cardiologia, v. 102, n. 3, 27, Feb. 2014.

Electronic Document Format (APA)

Redondo, A. C. C., Fuenmayor, G., Shiraishi, K. S., Fontes, S. R. F., Elias, P. F., Souza, R., & Jatene, I. B. (2014). Sildenafil for Noncompaction Cardiomyopathy Treatment in a Child: Case Report. Arquivos Brasileiros de Cardiologia, 102(3), 27.

Electronic Document Format (ISO)

Redondo, Ana Carolina Costa and Fuenmayor, Gabriela and Shiraishi, Karen Saori and Fontes, Simone Rolim F and Elias, Patrícia Figueiredo and Souza, Rogerio and Jatene, Ieda Biscegli. Sildenafil for Noncompaction Cardiomyopathy Treatment in a Child: Case Report. Arquivos Brasileiros de Cardiologia [online]. 2014, vol. 102, n. 3, [cited 2026-10-14], 27. Available from: <https://journals.cardiol.br/en/article/sildenafil-for-noncompaction-cardiomyopathy-treatment-in-a-child-case-report/>. ISSN 0066-782X

EndNote RIS

Electronic Document Format (Vancouver)

Silva AC, Toffoletto O, Lucio LAG, Santos PF, Afiune JB, Massud Filho J, Tufik S, et al. Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption. Arquivos Brasileiros de Cardiologia 2010;94(2):160-7.

Electronic Document Format (ABNT)

Silva, Adauto Carvalho; Toffoletto, Odaly; Lucio, Luiz Antonio Galvão; Santos, Paula Ferreira dos; Afiune, Jorge Barros; Massud Filho, João; Tufik, Sergio. Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption. Arquivos Brasileiros de Cardiologia, v. 94, n. 2, p. 160-167, May. 2010.

Electronic Document Format (APA)

Silva, A. C., Toffoletto, O., Lucio, L. A. G., Santos, P. F. , Afiune, J. B., Massud Filho, J., & Tufik, S. (2010). Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption. Arquivos Brasileiros de Cardiologia, 94(2), 160-167.

Electronic Document Format (ISO)

Silva, Adauto Carvalho and Toffoletto, Odaly and Lucio, Luiz Antonio Galvão and Santos, Paula Ferreira dos and Afiune, Jorge Barros and Massud Filho, João and Tufik, Sergio. Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption. Arquivos Brasileiros de Cardiologia [online]. 2010, vol. 94, n. 2, [cited 2026-10-14], pp. 160-167. Available from: <https://journals.cardiol.br/en/article/cardiovascular-repercussion-of-lodenafil-carbonate-a-new-pde5-inhibitor-with-and-without-alcohol-consumption/>. ISSN 0066-782X

  • About ABC Family
  • Internal Regulation
  • Editorial Board
  • Brazilian Society of Cardiology (SBC)

Issues

SBC Guidelines

  • Videos
  • Podcasts
  • News